Cidara Therapeutics (CDTX) Consolidated Net Income: 2017-2025
Historic Consolidated Net Income for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$83.2 million.
- Cidara Therapeutics' Consolidated Net Income fell 18396.22% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.4 million, marking a year-over-year decrease of 2564.97%. This contributed to the annual value of $464,000 for FY2024, which is 78.41% down from last year.
- Latest data reveals that Cidara Therapeutics reported Consolidated Net Income of -$83.2 million as of Q3 2025, which was down 223.64% from -$25.7 million recorded in Q2 2025.
- In the past 5 years, Cidara Therapeutics' Consolidated Net Income ranged from a high of $14.2 million in Q3 2022 and a low of -$83.2 million during Q3 2025.
- In the last 3 years, Cidara Therapeutics' Consolidated Net Income had a median value of -$450,000 in 2024 and averaged -$10.8 million.
- Per our database at Business Quant, Cidara Therapeutics' Consolidated Net Income skyrocketed by 178.78% in 2022 and then slumped by 18,396.22% in 2025.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Consolidated Net Income stood at -$16.8 million in 2021, then rose by 19.08% to -$13.6 million in 2022, then spiked by 136.54% to $5.0 million in 2023, then plummeted by 98.75% to $62,000 in 2024, then slumped by 18,396.22% to -$83.2 million in 2025.
- Its Consolidated Net Income was -$83.2 million in Q3 2025, compared to -$25.7 million in Q2 2025 and -$23.5 million in Q1 2025.